| Year |
Citation |
Score |
| 2022 |
Skovgaard D, Haahr PM, Lester R, Clark K, Paglialunga S, Finer N, Friedrichsen MH, Hjerpsted JB, Engelmann MDM. Prevalence of Baseline Cardiac Arrhythmias in Participants with Overweight or Obesity in Phase 1 Clinical Trials: Analysis of 24-Hour Holter Electrocardiogram Recordings. Journal of Clinical Pharmacology. PMID 36524539 DOI: 10.1002/jcph.2193 |
0.337 |
|
| 2021 |
Finer N. Weight loss interventions and nonalcoholic fatty liver disease: Optimizing liver outcomes. Diabetes, Obesity & Metabolism. PMID 34622555 DOI: 10.1111/dom.14569 |
0.353 |
|
| 2021 |
Finer N. Future directions in obesity pharmacotherapy. European Journal of Internal Medicine. PMID 34024701 DOI: 10.1016/j.ejim.2021.04.024 |
0.357 |
|
| 2021 |
Reges O, Dicker D, Haase CL, Finer N, Karpati T, Leibowitz M, Satylganova A, Feldman B. Body mass index trajectories among people with obesity and association with mortality: Evidence from a large Israeli database. Obesity Science & Practice. 7: 148-158. PMID 33841884 DOI: 10.1002/osp4.475 |
0.387 |
|
| 2020 |
Reges O, Leibowitz M, Hirsch A, Dicker D, Finer N, Haase CL, Satylganova A, Leventer-Roberts M, Feldman B. A comprehensive descriptive assessment of obesity related chronic morbidity and estimated annual cost burden from a population-based electronic health record database. Israel Journal of Health Policy Research. 9: 32. PMID 32580788 DOI: 10.1186/s13584-020-00378-1 |
0.393 |
|
| 2020 |
Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clinical Obesity. PMID 32342637 DOI: 10.1111/cob.12365 |
0.471 |
|
| 2019 |
Finer N. Weight loss for patients with obesity and heart failure. European Heart Journal. 40: 2139-2141. PMID 31180494 DOI: 10.1093/Eurheartj/Ehz406 |
0.447 |
|
| 2018 |
Suvan JE, Finer N, D'Aiuto F. Periodontal complications with obesity. Periodontology 2000. 78: 98-128. PMID 30198136 DOI: 10.1111/Prd.12239 |
0.438 |
|
| 2018 |
Brackenridge L, Finer N, Batterham RL, Pedram K, Ding T, Stephenson J, Barry J, Hardiman P. Pre-pregnancy weight loss in women with obesity requesting removal of their intra-uterine contraceptive device in order to conceive: a pilot study of full meal replacement. Clinical Obesity. PMID 29892993 DOI: 10.1111/cob.12252 |
0.436 |
|
| 2018 |
Kotsis V, Tsioufis K, Antza C, Seravalle G, Coca A, Sierra C, Lurbe E, Stabouli S, Jelakovic B, Redon J, Redon P, Nilsson PM, Jordan J, Micic D, Finer N, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part B: obesity-induced cardiovascular disease, early prevention strategies and future research directions. Journal of Hypertension. PMID 29652731 DOI: 10.1097/HJH.0000000000001731 |
0.484 |
|
| 2018 |
Kotsis V, Jordan J, Micic D, Finer N, Leitner DR, Toplak H, Tokgozoglu L, Athyros V, Elisaf M, Filippatos TD, Redon J, Redon P, Antza C, Tsioufis K, Grassi G, et al. Obesity and cardiovascular risk: a call for action from the European Society of Hypertension Working Group of Obesity, Diabetes and the High-risk Patient and European Association for the Study of Obesity: part A: mechanisms of obesity induced hypertension, diabetes and dyslipidemia and practice guidelines for treatment. Journal of Hypertension. PMID 29634663 DOI: 10.1097/HJH.0000000000001730 |
0.488 |
|
| 2017 |
Beeken RJ, Croker H, Heinrich M, Obichere A, Finer N, Murphy N, Goldin R, Guppy NJ, Wilson R, Fisher A, Steptoe A, Gunter MJ, Wardle J. The Impact of Diet-Induced Weight Loss on Biomarkers for Colorectal Cancer: An Exploratory Study (INTERCEPT). Obesity (Silver Spring, Md.). 25: S95-S101. PMID 29086510 DOI: 10.1002/oby.21984 |
0.301 |
|
| 2017 |
Pucci A, Tymoszuk U, Cheung WH, Makaronidis JM, Scholes S, Tharakan G, Elkalaawy M, Guimaraes M, Nora M, Hashemi M, Jenkinson A, Adamo M, Monteiro M, Finer N, Batterham RL. Type 2 diabetes remission 2 years post Roux-en-Y gastric bypass and sleeve gastrectomy: the role of the weight loss and comparison of DiaRem and DiaBetter scores. Diabetic Medicine : a Journal of the British Diabetic Association. PMID 29055156 DOI: 10.1111/dme.13532 |
0.311 |
|
| 2017 |
Welbourn R, Hopkins J, Dixon JB, Finer N, Hughes C, Viner R, Wass J. Commissioning guidance for weight assessment and management in adults and children with severe complex obesity. Obesity Reviews : An Official Journal of the International Association For the Study of Obesity. PMID 29024367 DOI: 10.1111/obr.12601 |
0.381 |
|
| 2016 |
Maggioni AP, Caterson ID, Urso R, Coutinho W, Finer N, Van Gaal L, Legler UF, Sharma AM, Seimon RV, Sweeting A, Torp-Pedersen C, James WP. Relation between weight loss and causes of death in patients with cardiovascular disease: finding from the SCOUT trial. Journal of Cardiovascular Medicine (Hagerstown, Md.). PMID 28002198 DOI: 10.2459/JCM.0000000000000492 |
0.478 |
|
| 2016 |
Mead E, Atkinson G, Richter B, Metzendorf MI, Baur L, Finer N, Corpeleijn E, O'Malley C, Ells LJ. Drug interventions for the treatment of obesity in children and adolescents. The Cochrane Database of Systematic Reviews. 11: CD012436. PMID 27899001 DOI: 10.1002/14651858.CD012436 |
0.399 |
|
| 2016 |
Kamil S, Finer N, James WP, Caterson ID, Andersson C, Torp-Pedersen C. Influence of sibutramine in addition to diet and exercise on the relationship between weight loss and blood glucose changes. European Heart Journal. Cardiovascular Pharmacotherapy. PMID 27680881 DOI: 10.1093/ehjcvp/pvw029 |
0.382 |
|
| 2016 |
Zomer E, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Effectiveness and cost-effectiveness of interventions that cause weight loss and reduce the risk of cardiovascular disease. Diabetes, Obesity & Metabolism. PMID 27649286 DOI: 10.1111/Dom.12792 |
0.409 |
|
| 2016 |
Uerlich MF, Yumuk V, Finer N, Basdevant A, Visscher TL. Obesity Management in Europe: Current Status and Objectives for the Future. Obesity Facts. 9: 273-283. PMID 27553443 DOI: 10.1159/000445192 |
0.44 |
|
| 2016 |
Jordan J, Toplak H, Grassi G, Yumuk V, Kotsis V, Engeli S, Cuspidi C, Nilsson PM, Finer N, Doehner W. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and heart failure. Journal of Hypertension. 34: 1678-88. PMID 27488547 DOI: 10.1097/HJH.0000000000001013 |
0.46 |
|
| 2016 |
Makaronidis JM, Neilson S, Cheung WH, Tymoszuk U, Pucci A, Finer N, Doyle J, Hashemi M, Elkalaawy M, Adamo M, Jenkinson A, Batterham RL. Reported appetite, taste and smell changes following Roux-en-Y gastric bypass and sleeve gastrectomy: Effect of gender, type 2 diabetes and relationship to post-operative weight loss. Appetite. PMID 27453553 DOI: 10.1016/j.appet.2016.07.029 |
0.323 |
|
| 2016 |
Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obesity Reviews : An Official Journal of the International Association For the Study of Obesity. PMID 27324830 DOI: 10.1111/Obr.12433 |
0.43 |
|
| 2016 |
Welbourn R, Dixon J, Barth JH, Finer N, Hughes CA, le Roux CW, Wass J. NICE-Accredited Commissioning Guidance for Weight Assessment and Management Clinics: a Model for a Specialist Multidisciplinary Team Approach for People with Severe Obesity. Obesity Surgery. PMID 26738895 DOI: 10.1007/s11695-015-2041-8 |
0.448 |
|
| 2016 |
Lenoir-Wijnkoop I, Mahon J, Claxton L, Wooding A, Prentice A, Finer N. An economic model for the use of yoghurt in type 2 diabetes risk reduction in the UK Bmc Nutrition. 2. DOI: 10.1186/s40795-016-0115-1 |
0.301 |
|
| 2015 |
Pucci A, Cheung WH, Jones J, Manning S, Kingett H, Adamo M, Elkalaawy M, Jenkinson A, Finer N, Doyle J, Hashemi M, Batterham RL. A case of severe anorexia, excessive weight loss and high peptide YY levels after sleeve gastrectomy. Endocrinology, Diabetes & Metabolism Case Reports. 2015: 150020. PMID 26664728 DOI: 10.1530/EDM-15-0020 |
0.427 |
|
| 2015 |
Leiter LA, Astrup A, Andrews RC, Cuevas A, Horn DB, Kunešová M, Wittert G, Finer N. Identification of educational needs in the management of overweight and obesity: results of an international survey of attitudes and practice. Clinical Obesity. PMID 26238414 DOI: 10.1111/cob.12109 |
0.467 |
|
| 2015 |
Finer N. Predicting therapeutic weight loss. The American Journal of Clinical Nutrition. 101: 419-20. PMID 25733622 DOI: 10.3945/ajcn.114.106195 |
0.462 |
|
| 2015 |
Pucci A, Finer N. New medications for treatment of obesity: metabolic and cardiovascular effects. The Canadian Journal of Cardiology. 31: 142-52. PMID 25661549 DOI: 10.1016/j.cjca.2014.11.010 |
0.476 |
|
| 2015 |
Jordan J, Nilsson PM, Kotsis V, Olsen MH, Grassi G, Yumuk V, Hauner H, Zahorska-Markiewicz B, Toplak H, Engeli S, Finer N. Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing. Journal of Hypertension. 33: 425-34. PMID 25629358 DOI: 10.1097/HJH.0000000000000473 |
0.467 |
|
| 2015 |
Finer N. Clinical obesity comes of age. Clinical Obesity. 5: 1. PMID 25611583 DOI: 10.1111/cob.12087 |
0.429 |
|
| 2015 |
Seimon RV, Espinoza D, Finer N, James WP, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial. International Journal of Obesity (2005). 39: 849-57. PMID 25520249 DOI: 10.1038/ijo.2014.211 |
0.469 |
|
| 2015 |
Manning S, Pucci A, Carter NC, Elkalaawy M, Querci G, Magno S, Tamberi A, Finer N, Fiennes AG, Hashemi M, Jenkinson AD, Anselmino M, Santini F, Adamo M, Batterham RL. Early postoperative weight loss predicts maximal weight loss after sleeve gastrectomy and Roux-en-Y gastric bypass. Surgical Endoscopy. 29: 1484-91. PMID 25239175 DOI: 10.1007/s00464-014-3829-7 |
0.352 |
|
| 2015 |
Finer N. Practice implications of NICE guidance on healthy weight Prescriber. 26: 5-6. DOI: 10.1002/psb.1365 |
0.344 |
|
| 2014 |
Manning S, Carter NC, Pucci A, Jones A, Elkalaawy M, Cheung WH, Mohammadi B, Finer N, Fiennes AG, Hashemi M, Jenkinson AD, Adamo M, Batterham RL. Age- and sex-specific effects on weight loss outcomes in a comparison of sleeve gastrectomy and Roux-en-Y gastric bypass: a retrospective cohort study. Bmc Obesity. 1: 12. PMID 26217504 DOI: 10.1186/2052-9538-1-12 |
0.367 |
|
| 2014 |
Manning S, Finer N, Elkalaawy M, Hashemi M, Jenkinson AD, Adamo M, O'Brien P, Batterham RL, Richens Y. Timing of pregnancy in obese women after bariatric surgery. Pregnancy Hypertension. 4: 235. PMID 26104622 DOI: 10.1016/j.preghy.2014.03.019 |
0.304 |
|
| 2014 |
Finer N. Comment on Balkau et al. Factors associated with weight gain in people with type 2 diabetes starting on insulin. Diabetes Care 2014;37:2108-2113. Diabetes Care. 37: e265. PMID 25414400 DOI: 10.2337/dc14-1916 |
0.348 |
|
| 2014 |
Finer N. Sarcopenic obesity: under recognised and over treated? Clinical Medicine (London, England). 14: 454. PMID 25099857 DOI: 10.7861/clinmedicine.14-4-454 |
0.475 |
|
| 2014 |
Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez-Kam M, Fraher K, Fain R, Shanahan WR. Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes. Obesity (Silver Spring, Md.). 22: 2137-46. PMID 25044799 DOI: 10.1002/oby.20841 |
0.399 |
|
| 2014 |
Charakida M, Khan T, Johnson W, Finer N, Woodside J, Whincup PH, Sattar N, Kuh D, Hardy R, Deanfield J. Lifelong patterns of BMI and cardiovascular phenotype in individuals aged 60-64 years in the 1946 British birth cohort study: an epidemiological study. The Lancet. Diabetes & Endocrinology. 2: 648-54. PMID 24856161 DOI: 10.1016/S2213-8587(14)70103-2 |
0.452 |
|
| 2014 |
Manning S, Pucci A, Finer N. Pharmacotherapy for obesity: novel agents and paradigms. Therapeutic Advances in Chronic Disease. 5: 135-48. PMID 24790728 DOI: 10.1177/2040622314522848 |
0.485 |
|
| 2014 |
Jordan J, Astrup A, Engeli S, Narkiewicz K, Day WW, Finer N. Cardiovascular effects of phentermine and topiramate: a new drug combination for the treatment of obesity. Journal of Hypertension. 32: 1178-88. PMID 24621808 DOI: 10.1097/HJH.0000000000000145 |
0.507 |
|
| 2014 |
Jørgensen ME, Torp-Pedersen C, Finer N, Caterson I, James WP, Legler UF, Andersson C. Association between serum bilirubin and cardiovascular disease in an overweight high risk population from the SCOUT trial. Nutrition, Metabolism, and Cardiovascular Diseases : Nmcd. 24: 656-62. PMID 24534073 DOI: 10.1016/j.numecd.2013.12.009 |
0.403 |
|
| 2014 |
Seimon RV, Espinoza D, Ivers L, Gebski V, Finer N, Legler UF, Sharma AM, James WP, Coutinho W, Caterson ID. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. International Journal of Obesity (2005). 38: 1165-71. PMID 24406481 DOI: 10.1038/ijo.2014.2 |
0.435 |
|
| 2014 |
Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL. Differential effects of laparoscopic sleeve gastrectomy and laparoscopic gastric bypass on appetite, circulating acyl-ghrelin, peptide YY3-36 and active GLP-1 levels in non-diabetic humans. Obesity Surgery. 24: 241-52. PMID 23996294 DOI: 10.1007/s11695-013-1066-0 |
0.385 |
|
| 2014 |
Lean ME, Carraro R, Finer N, Hartvig H, Lindegaard ML, Rössner S, Van Gaal L, Astrup A. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. International Journal of Obesity (2005). 38: 689-97. PMID 23942319 DOI: 10.1038/ijo.2013.149 |
0.469 |
|
| 2014 |
Winther SA, Finer N, Sharma AM, Torp-Pedersen C, Andersson C. Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. International Journal of Obesity (2005). 38: 432-7. PMID 23774460 DOI: 10.1038/ijo.2013.111 |
0.448 |
|
| 2014 |
Seimon RV, Espinoza D, Finer N, James PT, Legler UF, Coutinho W, Sharma AM, Van Gaal L, Maggioni AP, Sweeting A, Torp-Pedersen C, Gebski V, Caterson ID. Changes in Body Weight and Pulse: Outcome Events in Overweight and Obese Subjects with Cardiovascular Disease Obesity Research & Clinical Practice. 8: 90-91. DOI: 10.1016/J.ORCP.2014.10.166 |
0.398 |
|
| 2014 |
Finer N. Medical consequences of obesity Medicine (United Kingdom). 43: 88-93. DOI: 10.1016/j.mpmed.2014.11.003 |
0.481 |
|
| 2014 |
Smith SR, O'Neil PM, Astrup A, Finer N, Sanchez‐Kam M, Fraher K, Fain R, Shanahan WR. Erratum for: Early weight loss while on lorcaserin, diet, and exercise as a predictor of week 52 weight‐loss outcomes Obesity. 22: 2641-2641. DOI: 10.1002/Oby.20947 |
0.318 |
|
| 2013 |
Smith R, Finer N. Obesity and androgens: Masculinity or muscularity? Clinical Obesity. 3: 59-61. PMID 25586528 DOI: 10.1111/cob.12026 |
0.363 |
|
| 2013 |
Wass J, Finer N. Developing a specialist obesity infrastructure: an example from current strategies in England. Clinical Obesity. 3: 1-2. PMID 25586385 DOI: 10.1111/cob.12010 |
0.329 |
|
| 2013 |
Jackson SE, Wardle J, Johnson F, Finer N, Beeken RJ. The impact of a health professional recommendation on weight loss attempts in overweight and obese British adults: a cross-sectional analysis. Bmj Open. 3: e003693. PMID 24189083 DOI: 10.1136/bmjopen-2013-003693 |
0.488 |
|
| 2013 |
Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Diabetes Care. 36: 3746-53. PMID 24089540 DOI: 10.2337/dc13-0027 |
0.381 |
|
| 2013 |
Charakida M, Tousoulis D, Finer N. Drug treatment of obesity in the cardiovascular patient. Current Opinion in Cardiology. 28: 584-91. PMID 23928924 DOI: 10.1097/HCO.0b013e3283642a4c |
0.49 |
|
| 2013 |
Chowdhury TA, Finer N. Preventing diabetes: a call for concerted national action. Clinical Medicine (London, England). 13: 328-9. PMID 23908496 DOI: 10.7861/clinmedicine.13-4-328 |
0.348 |
|
| 2013 |
Manning SB, Pucci A, Batterham RL, Finer N. Latent autoimmune diabetes in adults presenting as diabetes "recurrence" after bariatric surgery: a case report. Diabetes Care. 36: e120. PMID 23881974 DOI: 10.2337/dc13-0810 |
0.361 |
|
| 2013 |
Lean M, Brosnahan N, McLoone P, McCombie L, Higgs AB, Ross H, Mackenzie M, Grieve E, Finer N, Reckless J, Haslam D, Sloan B, Morrison D. Feasibility and indicative results from a 12-month low-energy liquid diet treatment and maintenance programme for severe obesity. The British Journal of General Practice : the Journal of the Royal College of General Practitioners. 63: e115-24. PMID 23561690 DOI: 10.3399/bjgp13X663073 |
0.44 |
|
| 2013 |
Skak-Nielsen H, Torp-Pedersen C, Finer N, Caterson ID, Van Gaal L, James WP, Maggioni AP, Sharma AM, Coutinho W, Andersson C. Uric acid as a risk factor for cardiovascular disease and mortality in overweight/obese individuals. Plos One. 8: e59121. PMID 23533601 DOI: 10.1371/journal.pone.0059121 |
0.401 |
|
| 2013 |
Astrup A, Rössner S, Finer N, Van Gaal L. Obesity in Europe - does anybody care? Expert Opinion On Pharmacotherapy. 14: 971-3. PMID 23517073 DOI: 10.1517/14656566.2013.783016 |
0.422 |
|
| 2013 |
Wass J, Finer N. Action on obesity: comprehensive care for all. Clinical Medicine (London, England). 13: 4-5. PMID 23472483 DOI: 10.7861/clinmedicine.13-1-4 |
0.453 |
|
| 2012 |
Finer N. Better measures of fat mass - beyond BMI. Clinical Obesity. 2: 65. PMID 25586158 DOI: 10.1111/j.1758-8111.2012.00047.x |
0.306 |
|
| 2012 |
Finer N. Obesity and pre-diabetes. Clinical Obesity. 2: 1-2. PMID 25586040 DOI: 10.1111/j.1758-8111.2012.00046.x |
0.442 |
|
| 2012 |
Charakida M, Jones A, Falaschetti E, Khan T, Finer N, Sattar N, Hingorani A, Lawlor DA, Smith GD, Deanfield JE. Childhood obesity and vascular phenotypes: a population study. Journal of the American College of Cardiology. 60: 2643-50. PMID 23177297 DOI: 10.1016/j.jacc.2012.08.1017 |
0.363 |
|
| 2012 |
Mathus-Vliegen EMH, Basdevant A, Finer N, Hainer V, Hauner H, Micic D, Maislos M, Roman G, Schutz Y, Tsigos C, Toplak H, Yumuk V, Zahorska-Markiewicz B. Prevalence, pathophysiology, health consequences and treatment options of obesity in the elderly: A guideline Obesity Facts. 5: 460-483. PMID 22797374 DOI: 10.1159/000341193 |
0.394 |
|
| 2012 |
Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W, Couthino W, Finer N, Sharma AM, Maggioni AP, Torp-Pedersen C. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Diabetologia. 55: 2348-55. PMID 22638548 DOI: 10.1007/s00125-012-2584-3 |
0.449 |
|
| 2012 |
Jordan J, Yumuk V, Schlaich M, Nilsson PM, Zahorska-Markiewicz B, Grassi G, Schmieder RE, Engeli S, Finer N. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension. Journal of Hypertension. 30: 1047-55. PMID 22573071 DOI: 10.1097/HJH.0b013e3283537347 |
0.514 |
|
| 2012 |
Jones A, Charakida M, Falaschetti E, Hingorani AD, Finer N, Masi S, Donald AE, Lawlor DA, Smith GD, Deanfield JE. Adipose and height growth through childhood and blood pressure status in a large prospective cohort study. Hypertension. 59: 919-25. PMID 22493074 DOI: 10.1161/HYPERTENSIONAHA.111.187716 |
0.331 |
|
| 2012 |
Bell-Higgs AE, Brosnahan NT, Clarke AM, Dow MSA, Haynes SM, Lyons GF, McCombie E, Mongia S, Noble PA, Quinn MF, Regan PJ, Ross HM, Thompson FE, Vermeulen A, Iain Broom J, ... ... Finer N, et al. The implementation of the Counterweight programme in scotland, UK Family Practice. 29: i139-i144. PMID 22399544 DOI: 10.1093/fampra/cmr074 |
0.367 |
|
| 2012 |
Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions. 12: 93-104. PMID 22292446 DOI: 10.2165/11599000-000000000-00000 |
0.501 |
|
| 2012 |
Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obesity & Metabolism. 14: 523-30. PMID 22192338 DOI: 10.1111/j.1463-1326.2011.01554.x |
0.363 |
|
| 2012 |
Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L, Rasmussen MF, Rissanen A, Rössner S, Savolainen MJ, Van Gaal L. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. International Journal of Obesity (2005). 36: 843-54. PMID 21844879 DOI: 10.1038/ijo.2011.158 |
0.33 |
|
| 2012 |
Savory LA, Kerr CJ, Whiting P, Finer N, McEneny J, Ashton T. Selenium supplementation and exercise: effect on oxidant stress in overweight adults. Obesity (Silver Spring, Md.). 20: 794-801. PMID 21593809 DOI: 10.1038/oby.2011.83 |
0.327 |
|
| 2012 |
White B, Finer N, Adamo M, Duke E, Kingett H, Christie D, Doyle J, Batterham R, Viner R. Outcomes of an adolescent bariatric service Archives of Disease in Childhood. 97. DOI: 10.1136/Archdischild-2012-301885.152 |
0.314 |
|
| 2011 |
Finer N. Clinical Obesity - a new journal for a new clinical era. Clinical Obesity. 1: 1-2. PMID 25586969 DOI: 10.1111/j.1758-8111.2010.00001.x |
0.38 |
|
| 2011 |
Finer N. New targets for obesity pharmacotherapy - developing anti-obesity drugs that do not necessarily produce weight loss. Clinical Obesity. 1: 61. PMID 25585569 DOI: 10.1111/j.1758-8111.2011.00023.x |
0.389 |
|
| 2011 |
Tsigos C, Hainer V, Basdevant A, Finer N, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Yumuk V, Zahorska-Markiewicz B. Criteria for EASO-collaborating centres for obesity management. Obesity Facts. 4: 329-33. PMID 21921658 DOI: 10.1159/000331236 |
0.47 |
|
| 2011 |
Aronne LJ, Finer N, Hollander PA, England RD, Klioze SS, Chew RD, Fountaine RJ, Powell CM, Obourn JD. Efficacy and safety of CP-945,598, a selective cannabinoid CB1 receptor antagonist, on weight loss and maintenance. Obesity (Silver Spring, Md.). 19: 1404-14. PMID 21293451 DOI: 10.1038/oby.2010.352 |
0.401 |
|
| 2010 |
Falaschetti E, Hingorani AD, Jones A, Charakida M, Finer N, Whincup P, Lawlor DA, Davey Smith G, Sattar N, Deanfield JE. Adiposity and cardiovascular risk factors in a large contemporary population of pre-pubertal children. European Heart Journal. 31: 3063-72. PMID 20972265 DOI: 10.1093/eurheartj/ehq355 |
0.402 |
|
| 2010 |
James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. The New England Journal of Medicine. 363: 905-17. PMID 20818901 DOI: 10.1056/NEJMoa1003114 |
0.393 |
|
| 2010 |
Trueman P, Haynes SM, Felicity Lyons G, Louise McCombie E, McQuigg MS, Mongia S, Noble PA, Quinn MF, Ross HM, Thompson F, Broom JI, Laws RA, Reckless JP, Kumar S, Lean ME, ... ... Finer N, et al. Long-term cost-effectiveness of weight management in primary care. International Journal of Clinical Practice. 64: 775-83. PMID 20353431 DOI: 10.1111/j.1742-1241.2010.02349.x |
0.449 |
|
| 2010 |
Finer N. Withdrawal of sibutramine. Editorial is judgment in advance of the facts. Bmj (Clinical Research Ed.). 340: c1346. PMID 20219799 DOI: 10.1136/bmj.c1346 |
0.373 |
|
| 2010 |
Weeke P, Andersson C, Fosbøl EL, Brendorp B, Køber L, Sharma AM, Finer N, James PT, Caterson ID, Rode RA, Torp-Pedersen C. The weight lowering effect of sibutramine and its impact on serum lipids in cardiovascular high risk patients with and without type 2 diabetes mellitus - an analysis from the SCOUT lead-in period. Bmc Endocrine Disorders. 10: 3. PMID 20184783 DOI: 10.1186/1472-6823-10-3 |
0.387 |
|
| 2010 |
Pendergast K, Wolf A, Sherrill B, Zhou X, Aronne LJ, Caterson I, Finer N, Hauner H, Hill J, Van Gaal L, Coste F, Despres JP. Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 13: 402-10. PMID 20113460 DOI: 10.1111/J.1524-4733.2009.00690.X |
0.455 |
|
| 2010 |
Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C, Sharma AM, Ge H, Santoro D, Shepherd G, James P. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring, Md.). 18: 987-94. PMID 19816415 DOI: 10.1038/oby.2009.327 |
0.366 |
|
| 2010 |
Van Gaal LF, Caterson ID, Coutinho W, Finer N, Maggioni AP, Sharma AM, Torp-Pedersen C, Ge H, Moran SA, Shepherd GM, James WP. Weight and blood pressure response to weight management and sibutramine in diabetic and non-diabetic high-risk patients: an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes (SCOUT) trial. Diabetes, Obesity & Metabolism. 12: 26-34. PMID 19758358 DOI: 10.1111/j.1463-1326.2009.01090.x |
0.377 |
|
| 2010 |
Swe Myint K, Napolitano A, Miller SR, Murgatroyd PR, Elkhawad M, Nunez DJ, Finer N. Quantitative magnetic resonance (QMR) for longitudinal evaluation of body composition changes with two dietary regimens. Obesity (Silver Spring, Md.). 18: 391-6. PMID 19696753 DOI: 10.1038/oby.2009.272 |
0.379 |
|
| 2010 |
James P, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma AM. EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL Journal of the American College of Cardiology. 55: A141.E1326. DOI: 10.1016/S0735-1097(10)61327-7 |
0.422 |
|
| 2009 |
Sharma V, Braithwaite A, Harger S, Finer N. Obesity remains under diagnosed in English hospital in-patients. Obesity Research & Clinical Practice. 3: 1-52. PMID 24345537 DOI: 10.1016/j.orcp.2008.10.001 |
0.451 |
|
| 2009 |
Andersson C, Weeke P, Brendorp B, Køber L, Fosbøl EL, Sharma AM, Finer N, Caterson ID, Rode RA, James PT, Torp-Pedersen C. Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial. Nutrition & Metabolism. 6: 42. PMID 19828038 DOI: 10.1186/1743-7075-6-42 |
0.437 |
|
| 2009 |
Andersson C, Weeke P, Fosbøl EL, Brendorp B, Køber L, Coutinho W, Sharma AM, Van Gaal L, Finer N, James WP, Caterson ID, Rode RA, Torp-Pedersen C. Acute effect of weight loss on levels of total bilirubin in obese, cardiovascular high-risk patients: an analysis from the lead-in period of the Sibutramine Cardiovascular Outcome trial. Metabolism: Clinical and Experimental. 58: 1109-15. PMID 19454355 DOI: 10.1016/j.metabol.2009.04.003 |
0.469 |
|
| 2009 |
Brown LA, Kerr CJ, Whiting P, Finer N, McEneny J, Ashton T. Oxidant stress in healthy normal-weight, overweight, and obese individuals. Obesity (Silver Spring, Md.). 17: 460-6. PMID 19131942 DOI: 10.1038/oby.2008.590 |
0.467 |
|
| 2009 |
Sharma AM, Caterson ID, Coutinho W, Finer N, Van Gaal L, Maggioni AP, Torp-Pedersen C, Bacher HP, Shepherd GM, James WP. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT). Diabetes, Obesity & Metabolism. 11: 239-50. PMID 18671798 DOI: 10.1111/j.1463-1326.2008.00930.x |
0.329 |
|
| 2009 |
Finer N. Alli: a friend to the overweight Prescriber. 20: 6-6. DOI: 10.1002/psb.536 |
0.458 |
|
| 2008 |
McQuigg M, Brown JE, Broom J, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons FG, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, et al. The Counterweight programme: Prevalence of CVD risk factors by body mass index and the impact of 10% weight change. Obesity Research & Clinical Practice. 2: I-II. PMID 24351674 DOI: 10.1016/j.orcp.2008.01.002 |
0.471 |
|
| 2008 |
Tsigos C, Hainer V, Basdevant A, Finer N, Fried M, Mathus-Vliegen E, Micic D, Maislos M, Roman G, Schutz Y, Toplak H, Zahorska-Markiewicz B. Management of obesity in adults: European clinical practice guidelines. Obesity Facts. 1: 106-16. PMID 20054170 DOI: 10.1159/000126822 |
0.44 |
|
| 2008 |
Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Interdisciplinary European guidelines on surgery of severe obesity. Obesity Facts. 1: 52-9. PMID 20054163 DOI: 10.1159/000113937 |
0.471 |
|
| 2008 |
Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. [Interdisciplinary European guidelines on surgery for severe obesity]. Rozhledy V Chirurgii : MěSíčNíK čEskoslovenské Chirurgické SpolečNosti. 87: 468-76. PMID 19174948 |
0.313 |
|
| 2008 |
McQuigg M, Brown JE, Broom JI, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons GF, Mongia S, Frost GS, Quinn MF, Barth JH, ... ... Finer N, et al. Engaging patients, clinicians and health funders in weight management: the Counterweight Programme. Family Practice. 25: i79-86. PMID 19042914 DOI: 10.1093/fampra/cmn081 |
0.32 |
|
| 2008 |
Maggioni AP, Caterson I, Coutinho W, Finer N, Gaal LV, Sharma AM, Torp-Pedersen C, Bacher P, Shepherd G, Sun R, James P. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. Journal of Cardiovascular Pharmacology. 52: 393-402. PMID 19033818 DOI: 10.1097/FJC.0b013e31818713d6 |
0.445 |
|
| 2008 |
Wolf AM, Finer N, Allshouse AA, Pendergast KB, Sherrill BH, Caterson I, Hill JO, Aronne LJ, Hauner H, Radigue C, Amand C, Despres JP. PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample. Diabetes, Obesity & Metabolism. 10: 1248-60. PMID 18721258 DOI: 10.1111/j.1463-1326.2008.00895.x |
0.476 |
|
| 2008 |
Fried M, Hainer V, Basdevant A, Buchwald H, Dietel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. [Inter-disciplinary European guidelines on surgery of severe obesity]. Vnitrì†Nã Lã©Karì†Stvã. 54: 421-9. PMID 18630623 |
0.313 |
|
| 2008 |
Goodman AO, Murgatroyd PR, Medina-Gomez G, Wood NI, Finer N, Vidal-Puig AJ, Morton AJ, Barker RA. The metabolic profile of early Huntington's disease--a combined human and transgenic mouse study. Experimental Neurology. 210: 691-8. PMID 18284928 DOI: 10.1016/j.expneurol.2007.12.026 |
0.3 |
|
| 2008 |
Napolitano A, Miller SR, Murgatroyd PR, Coward WA, Wright A, Finer N, De Bruin TW, Bullmore ET, Nunez DJ. Validation of a quantitative magnetic resonance method for measuring human body composition. Obesity (Silver Spring, Md.). 16: 191-8. PMID 18223634 DOI: 10.1038/oby.2007.29 |
0.318 |
|
| 2008 |
Elfhag K, Finer N, Rössner S. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success. Diabetes, Obesity & Metabolism. 10: 498-505. PMID 17593239 DOI: 10.1111/j.1463-1326.2007.00740.x |
0.408 |
|
| 2008 |
Wilding J, Finer N. Weight management and cardiovascular disease: Implications of recent and ongoing clinical trials British Journal of Diabetes and Vascular Disease. 8: 170-176. DOI: 10.1177/1474651408094587 |
0.525 |
|
| 2007 |
Wittert G, Caterson I, Finer N. The clinical effectiveness of weight loss drugs. Obesity Research & Clinical Practice. 1: 1-78. PMID 24351426 DOI: 10.1016/j.orcp.2006.12.001 |
0.518 |
|
| 2007 |
Levy P, Fried M, Santini F, Finer N. The comparative effects of bariatric surgery on weight and type 2 diabetes. Obesity Surgery. 17: 1248-56. PMID 18074502 DOI: 10.1007/s11695-007-9214-z |
0.426 |
|
| 2007 |
Torp-Pedersen C, Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Sharma A, Brisco W, Deaton R, Shepherd G, James P. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. European Heart Journal. 28: 2915-23. PMID 17595194 DOI: 10.1093/eurheartj/ehm217 |
0.419 |
|
| 2007 |
Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obesity Surgery. 17: 260-70. PMID 17476884 DOI: 10.1007/s11695-007-9025-2 |
0.467 |
|
| 2007 |
Finer N. Drug treatments for obesity. Lancet. 369: 1163; author reply 1. PMID 17416251 DOI: 10.1016/S0140-6736(07)60552-2 |
0.424 |
|
| 2007 |
Fried M, Hainer V, Basdevant A, Buchwald H, Deitel M, Finer N, Greve JW, Horber F, Mathus-Vliegen E, Scopinaro N, Steffen R, Tsigos C, Weiner R, Widhalm K. Inter-disciplinary European guidelines on surgery of severe obesity. International Journal of Obesity (2005). 31: 569-77. PMID 17325689 DOI: 10.1038/sj.ijo.0803560 |
0.472 |
|
| 2007 |
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Rimonabant in obese patients with type 2 diabetes - Authors' reply Lancet. 369: 554-555. DOI: 10.1016/S0140-6736(07)60264-5 |
0.431 |
|
| 2006 |
Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet. 368: 1660-72. PMID 17098084 DOI: 10.1016/S0140-6736(06)69571-8 |
0.457 |
|
| 2006 |
Lean M, Finer N. ABC of obesity. Management: part II--drugs. Bmj (Clinical Research Ed.). 333: 794-7. PMID 17038738 DOI: 10.1136/bmj.333.7572.794 |
0.47 |
|
| 2006 |
Caterson ID, Finer N. Emerging pharmacotherapy for treating obesity and associated cardiometabolic risk. Asia Pacific Journal of Clinical Nutrition. 15: 55-62. PMID 16928662 |
0.434 |
|
| 2006 |
López M, Lelliott CJ, Tovar S, Kimber W, Gallego R, Virtue S, Blount M, Vázquez MJ, Finer N, Powles TJ, O'Rahilly S, Saha AK, Diéguez C, Vidal-Puig AJ. Tamoxifen-induced anorexia is associated with fatty acid synthase inhibition in the ventromedial nucleus of the hypothalamus and accumulation of malonyl-CoA. Diabetes. 55: 1327-36. PMID 16644689 DOI: 10.2337/db05-1356 |
0.351 |
|
| 2006 |
Tuthill A, Slawik H, O'Rahilly S, Finer N. Psychiatric co-morbidities in patients attending specialist obesity services in the UK. Qjm : Monthly Journal of the Association of Physicians. 99: 317-25. PMID 16613993 DOI: 10.1093/Qjmed/Hcl041 |
0.419 |
|
| 2006 |
Wilding J, Finer N. Obesity and risk of myocardial infarction: the INTERHEART study. Lancet. 367: 1053; author reply 1. PMID 16581397 DOI: 10.1016/S0140-6736(06)68463-8 |
0.409 |
|
| 2006 |
Finer N, Ryan DH, Renz CL, Hewkin AC. Prediction of response to sibutramine therapy in obese non-diabetic and diabetic patients. Diabetes, Obesity & Metabolism. 8: 206-13. PMID 16448525 DOI: 10.1111/j.1463-1326.2005.00481.x |
0.423 |
|
| 2005 |
Finer N. Rationing joint replacements: trust's decision seems to be based on prejudice or attributing blame... Bmj (Clinical Research Ed.). 331: 1472. PMID 16356989 DOI: 10.1136/bmj.331.7530.1472-a |
0.327 |
|
| 2005 |
Zelissen PM, Stenlof K, Lean ME, Fogteloo J, Keulen ET, Wilding J, Finer N, Rössner S, Lawrence E, Fletcher C, McCamish M. Effect of three treatment schedules of recombinant methionyl human leptin on body weight in obese adults: a randomized, placebo-controlled trial. Diabetes, Obesity & Metabolism. 7: 755-61. PMID 16219020 DOI: 10.1111/j.1463-1326.2005.00468.x |
0.469 |
|
| 2005 |
Frost G, Broom JI, Brown JE, McQuigg MS, Laws RA, Reckless JP, Kumar S, Noble PA, Hole DJ, Lean ME, Louise McCombie E, Barth JH, Quinn MF, Frost GS, Lyons GF, ... Finer N, et al. Obesity impacts on general practice appointments Obesity Research. 13: 1442-1449. PMID 16129727 |
0.343 |
|
| 2005 |
McQuigg M, Brown J, Broom J, Laws RA, Reckless JP, Noble PA, Kumar S, McCombie EL, Lean ME, Lyons GF, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, et al. Empowering primary care to tackle the obesity epidemic: the Counterweight Programme. European Journal of Clinical Nutrition. 59: S93-100; discussion . PMID 16052202 DOI: 10.1038/sj.ejcn.1602180 |
0.47 |
|
| 2005 |
Packianathan I, Sheikh M, Boniface D, Finer N. Predictors of programme adherence and weight loss in women in an obesity programme using meal replacements. Diabetes, Obesity & Metabolism. 7: 439-47. PMID 15955131 DOI: 10.1111/j.1463-1326.2004.00451.x |
0.4 |
|
| 2005 |
Packianathan IC, Fuller NJ, Peterson DB, Wright A, Coward WA, Finer N. Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the 'Darwin study'. Diabetologia. 48: 222-9. PMID 15688205 DOI: 10.1007/s00125-004-1642-x |
0.336 |
|
| 2005 |
Sauerland S, Angrisani L, Belachew M, Chevallier JM, Favretti F, Finer N, Fingerhut A, Garcia Caballero M, Guisado Macias JA, Mittermair R, Morino M, Msika S, Rubino F, Tacchino R, Weiner R, et al. Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surgical Endoscopy. 19: 200-21. PMID 15580436 DOI: 10.1007/s00464-004-9194-1 |
0.421 |
|
| 2005 |
Finer N, Pagotto U. Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management The British Journal of Diabetes & Vascular Disease. 5: 121-124. DOI: 10.1177/14746514050050030201 |
0.396 |
|
| 2005 |
Finer N. Does pharmacologically induced weight loss improve cardiovascular outcome? Impact of anti-obesity agents on cardiovascular risk factors European Heart Journal, Supplement. 7: L32-L38. DOI: 10.1093/eurheartj/sui084 |
0.489 |
|
| 2004 |
Gibbs HD, Broom J, Brown J, Laws RA, Reckless JPD, Noble PA, Kumar S, McCombie EL, Lean MEJ, Lyons FG, Frost GS, Quinn MF, Barth JH, Haynes SM, Finer N, et al. Current approaches to obesity management in UK Primary Care: the Counterweight Programme. Journal of Human Nutrition and Dietetics. 17: 183-190. PMID 15139890 DOI: 10.1111/J.1365-277X.2004.00528.X |
0.492 |
|
| 2004 |
Finer N. Atlas of Obesity and Weight Control Clinical Endocrinology. 60: 150-150. DOI: 10.1111/J.1365-2265.2004.01934.X |
0.498 |
|
| 2003 |
Morris PJ, Packianathan CI, Van Blerk CJ, Finer N. Moderate exercise and fibrinolytic potential in obese sedentary men with metabolic syndrome. Obesity Research. 11: 1333-8. PMID 14627753 DOI: 10.1038/oby.2003.180 |
0.386 |
|
| 2003 |
van Baak MA, van Mil E, Astrup AV, Finer N, Van Gaal LF, Hilsted J, Kopelman PG, Rössner S, James WP, Saris WH. Leisure-time activity is an important determinant of long-term weight maintenance after weight loss in the Sibutramine Trial on Obesity Reduction and Maintenance (STORM trial). The American Journal of Clinical Nutrition. 78: 209-14. PMID 12885699 DOI: 10.1093/Ajcn/78.2.209 |
0.465 |
|
| 2003 |
Finer N. Obesity. Clinical Medicine (London, England). 3: 23-7. PMID 12617409 |
0.371 |
|
| 2002 |
Packianathan IC, Sheikh M, Feben S, Finer N. The Eating Disorder Inventory in a UK National Health Service Obesity Clinic and its response to modest weight loss. Eating Behaviors. 3: 275-84. PMID 15001005 DOI: 10.1016/S1471-0153(02)00063-6 |
0.507 |
|
| 2002 |
Finer N. Pharmacotherapy of obesity. Best Practice & Research. Clinical Endocrinology & Metabolism. 16: 717-42. PMID 12468417 DOI: 10.1053/Beem.2002.0231 |
0.518 |
|
| 2002 |
Finer N. Sibutramine: its mode of action and efficacy. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 26: S29-33. PMID 12457297 DOI: 10.1038/sj.ijo.0802216 |
0.42 |
|
| 2002 |
Krebs JD, Evans S, Cooney L, Mishra GD, Fruhbeck G, Finer N, Jebb SA. Changes in risk factors for cardiovascular disease with body fat loss in obese women. Diabetes, Obesity & Metabolism. 4: 379-87. PMID 12406035 DOI: 10.1046/J.1463-1326.2002.00231.X |
0.505 |
|
| 2001 |
Finer N. Sibutramine in clinical practice. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 25: S12-5. PMID 11916099 DOI: 10.1038/Sj.Ijo.0801932 |
0.397 |
|
| 2001 |
Finer N. Low-calorie diets and sustained weight loss. Obesity Research. 9: 290S-294S. PMID 11707556 DOI: 10.1038/oby.2001.133 |
0.405 |
|
| 2001 |
Kopelman PG, Finer N. Reply: Is obesity a disease? International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 25: 1405-6. PMID 11673758 DOI: 10.1038/sj.ijo.0801791 |
0.452 |
|
| 2001 |
Hansen D, Astrup A, Toubro S, Finer N, Kopelman P, Hilsted J, Rössner S, Saris W, Van Gaal L, James W, Goulder M. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 25: 496-501. PMID 11319653 DOI: 10.1038/sj.ijo.0801481 |
0.475 |
|
| 2001 |
Morris PJ, Finer N, Blerk CJV. The Effect Of Moderate Exercise On Plasminogen Activator Inhibitor In Obese Vs Non Obese Sedentary Males Medicine and Science in Sports and Exercise. 33. DOI: 10.1097/00005768-200105001-00444 |
0.441 |
|
| 2001 |
James WPT, Astrup A, Finer N. Drug therapy for management of obesity The Lancet. 357: 1288. DOI: 10.1016/S0140-6736(00)04426-3 |
0.396 |
|
| 2000 |
Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obesity Reviews : An Official Journal of the International Association For the Study of Obesity. 1: 57-9. PMID 12119987 DOI: 10.1046/J.1467-789X.2000.00013.X |
0.403 |
|
| 2000 |
Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes, Obesity & Metabolism. 2: 105-12. PMID 11220522 DOI: 10.1046/J.1463-1326.2000.00071.X |
0.423 |
|
| 2000 |
James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rössner S, Saris WH, Van Gaal LF. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 356: 2119-25. PMID 11191537 DOI: 10.1016/S0140-6736(00)03491-7 |
0.459 |
|
| 2000 |
Finer N. Prevention and management of obesity: pharmacology . The Proceedings of the Nutrition Society. 59: 413. PMID 10997657 |
0.338 |
|
| 2000 |
Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 24: 306-13. PMID 10757623 DOI: 10.1038/Sj.Ijo.0801128 |
0.464 |
|
| 1999 |
Hughes D, McGuire A, Elliot H, Finer N, Lean M, Prentice AM, Ritchie L. The Cost of Obesity in the United Kingdom Journal of Medical Economics. 2: 143-153. DOI: 10.3111/199902143153 |
0.442 |
|
| 1997 |
Finer N. Present and future pharmacological approaches. British Medical Bulletin. 53: 409-32. PMID 9246843 DOI: 10.1093/Oxfordjournals.Bmb.A011620 |
0.389 |
|
| 1994 |
Kopelman PG, Finer N, Fox KR, Hill A, MacDonald IA. ASO consensus statement on obesity. UK Association for the Study of Obesity. International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association For the Study of Obesity. 18: 189-91. PMID 8044191 |
0.375 |
|
| 1992 |
Finer N, Finer S, Naoumova RP. Drug therapy after very-low-calorie diets. The American Journal of Clinical Nutrition. 56: 195S-198S. PMID 1615883 DOI: 10.1093/Ajcn/56.1.195S |
0.454 |
|
| 1992 |
Finer N. Serotoninergic system: therapeutic implications in obesity. Acta Clinica Belgica. 14: 47-51. PMID 1604961 DOI: 10.1080/17843286.1992.11718276 |
0.47 |
|
| 1988 |
Caballero B, Finer N, Wurtman RJ. Plasma amino acids and insulin levels in obesity: response to carbohydrate intake and tryptophan supplements. Metabolism: Clinical and Experimental. 37: 672-6. PMID 3290625 DOI: 10.1016/0026-0495(88)90089-3 |
0.668 |
|
| 1987 |
Finer N, Price P, Grossman A, Besser GM. The effect of enkephalin analogue on pituitary hormone release in human obesity. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme. 19: 68-70. PMID 3104184 DOI: 10.1055/S-2007-1011741 |
0.454 |
|
| 1987 |
Finer N, Naoumova R, Finer S. Very Low Calorie Diet and Noradrenaline-Induced Thermogenesis in Human Obesity Clinical Science. 73: 17P-17P. DOI: 10.1042/cs073017p |
0.432 |
|
| 1986 |
Lieberman HR, Caballero B, Finer N. The composition of lunch determines afternoon plasma tryptophan ratios in humans. Journal of Neural Transmission. 65: 211-7. PMID 3711884 DOI: 10.1007/BF01249083 |
0.575 |
|
| 1986 |
Finer N, Swan PC, Mitchell FT. Metabolic rate after massive weight loss in human obesity. Clinical Science (London, England : 1979). 70: 395-8. PMID 3698515 DOI: 10.1042/CS0700395 |
0.457 |
|
| 1984 |
Finer N, Grossman A, Price P. The Effect of Enkephalin Analogue (DAMME) on Pituitary Hormone Release in Human Obesity Clinical Science. 67: 19P-20P. DOI: 10.1042/cs067019pb |
0.39 |
|
| 1984 |
Finer N, Swan PC, Naylor MN. The Effect of Diet and Weight Loss on Thermogenesis in Massive Human Obesity Clinical Science. 66: 45P-45P. DOI: 10.1042/cs066045p_pt2 |
0.488 |
|
| 1983 |
Finer N, Swan P, Keen H. Diet and Noradrenaline Induced Thermocenesis in Massive Obesity Clinical Science. 65: 23P-23P. DOI: 10.1042/CS065023P |
0.446 |
|
| Show low-probability matches. |